Search results for "C25"

showing 6 items of 566 documents

The matrix metalloproteinase and insulin-like growth factor system in oral cancer – a prospective clinical study

2017

Eik Schiegnitz,1 Peer W Kämmerer,2 Holger Schön,1 Christoph Gülle,1 Manfred Berres,3,4 Keyvan Sagheb,1 Bilal Al-Nawas5 1Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Center, Johannes Gutenberg University of Mainz, Mainz, 2Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Centre Rostock, Rostock, 3Department of Mathematics and Technology, University of Applied Sciences Koblenz, Remagen, 4Institute of Medical Biometry, Epidemiology and Informatics, Johannes Gutenberg University of Mainz, Mainz, 5Department of Oral and Maxillofacial Surgery, Plastic Surgery, University Medical Centre, Martin-Luther University Ha…

stomatognathic diseasesserum biomarkerOSCCoral premalignant lesionprognosisoral cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282OncoTargets and Therapy
researchProduct

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer

2020

ABSTRACT Glucocorticosteroids (GCS) have an established role in oncology and are administered to cancer patients in routine clinical care and in drug development trials as co-medication. Given their strong immune-suppressive activity, GCS may interfere with immune-oncology drugs. We are developing a therapeutic cancer vaccine, which is based on a liposomal formulation of tumor-antigen encoding RNA (RNA-LPX) and induces a strong T-cell response both in mice as well as in humans. In this study, we investigated in vivo in mice and in human PBMCs the effect of the commonly used long-acting GCS Dexamethasone (Dexa) on the efficacy of this vaccine format, with a particular focus on antigen-specif…

t-cell primingPremedicationmedicine.medical_treatmentImmunologyPriming (immunology)dexamethasoneglucocorticosteroidsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineImmune systemAntigenCancer immunotherapyNeoplasmsAnimalsHumansImmunology and AllergyMedicineRC254-282Original ResearchMice Inbred BALB Ccancer immunotherapybusiness.industryrna vaccineImmunityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC581-607Mice Inbred C57BLCytokineOncology030220 oncology & carcinogenesisImmunologyt-cell vaccineFemaleCancer vaccineImmunologic diseases. AllergybusinessT-cell vaccineResearch Article030215 immunologyOncoImmunology
researchProduct

Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma

2020

Osteolytic bone disease is the major complication associated with the progression of multiple myeloma (MM). Recently, extracellular vesicles (EVs) have emerged as mediators of MM-associated bone disease by inhibiting the osteogenic differentiation of human mesenchymal stem cells (hMSCs). Here, we investigated a correlation between the EV-mediated osteogenic inhibition and MM vesicle content, focusing on miRNAs. By the use of a MicroRNA Card, we identified a pool of miRNAs, highly expressed in EVs, from MM cell line (MM1.S EVs), expression of which was confirmed in EVs from bone marrow (BM) plasma of patients affected by smoldering myeloma (SMM) and MM. Notably,we found that miR-129-5p, whic…

transcription factor sp1.Cancer ResearchBone diseaseosteogenic differentiationexosomeslcsh:RC254-282transcription factor sp1ArticleSettore MED/15 - Malattie Del SangueSettore BIO/13 - Biologia Applicatamedicinemultiple myeloma (MM)ChemistrySettore BIO/16 - Anatomia UmanaMesenchymal stem cellALPLOsteoblastMicroRNAExtracellular vesiclemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore CHIM/08 - Chimica FarmaceuticaCell biologymicroRNAsExosomemedicine.anatomical_structureOncologyCell cultureAlkaline phosphatasebone diseaseBone marrowextracellular vesicles (EVs)Cancers
researchProduct

Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States

2020

Background: Breast cancer treatment has changed tremendously over the last decades. In addition, the use of mammography screening for early detection has increased strongly. To evaluate the impact of these developments, long-term trends in incidence, mortality, stage distribution and survival were investigated for Germany and the United States (US). Methods: Using population-based cancer registry data, long-term incidence and mortality trends (1975&ndash

trendsCancer ResearchUnited States ; Survival ; Trends ; Mortality ; Incidence ; Breast cancer ; GermanyBreast cancer mortalityPopulationsurvivallcsh:RC254-282Article03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerGermanyMedicine030212 general & internal medicineStage (cooking)Mortality trendseducationeducation.field_of_studyRelative survivalbusiness.industryIncidence (epidemiology)lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemortalityUnited StatesCancer registryOncology030220 oncology & carcinogenesisincidencebusinessDemographyCancers
researchProduct

Extracellular Vesicles as Shuttles of Tumor Biomarkers and Anti-Tumor Drugs

2014

Extracellular vesicles (EV) include vesicles released by either normal or tumor cells. EV may exceed the nanometric scale (microvesicles), or to be within the nanoscale, also called exosomes. Thus, it appears that only exosomes and larger vesicles may have the size for potential applications in nanomedicine, in either disease diagnosis or therapy. This is of particular interest for research in cancer, also because the vast majority of existing data on EV are coming from pre-clinical and clinical oncology. We know that the microenvironmental features of cancer may favor cell-to-cell paracrine communication through EV, but EV have been purified, characterized, and quantified from plasma of tu…

tumorsCancer Researchbusiness.industryVesicleParacrine CommunicationbiomarkersCancerexosomeslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBioinformaticsmedicine.diseaselcsh:RC254-282Extracellular vesiclesMicrovesiclesAnti-Tumor DrugsteranosticsTumor BiomarkersOncologyPerspective ArticleCancer researchmedicineNanomedicineextracellular vesiclesbusinessFrontiers in Oncology
researchProduct

Immune responses during COVID-19 infection

2020

International audience; Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and 2015, and SARS-CoV-2 in 2020, have been causing severe and fatal human epidemics. The unpredictability of coronavirus disease-19 (COVID-19) poses a major burden on health care and economic systems across the world. This is caused by the paucity of in-depth knowledge of the risk factors for severe COVID-19, insufficient diagnostic tools for the detection of SARS-CoV-2, as well as the absence of specific and effective drug treatments. While protective humoral and cellular immune responses are usually m…

virusesReviewmedicine.disease_causeDiagnostic toolsSeverity of Illness Index[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityimmune responsehumoral0302 clinical medicineRisk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesImmunology and AllergyRC254-282Coronavirus[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseasesImmunity Cellular[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensvirus diseases3. Good healthOncologySevere acute respiratory syndrome-related coronavirus[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology030220 oncology & carcinogenesis[SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunologyMiddle East Respiratory Syndrome Coronavirus[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCovid-19Coronavirus disease 2019 (COVID-19)Sars-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immunology03 medical and health sciencesImmune systemIntensive caremedicineHumans[SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunityHost Microbial Interactionsbusiness.industryRC581-607Protective Factorsbiochemical phenomena metabolism and nutritionmedicine.diseaseimmunityImmunity HumoralClinical trialCoronavirusImmunologyMiddle East respiratory syndromeImmunologic diseases. Allergybusinesscellular030215 immunology
researchProduct